Protein expression is a process in which proteins are synthesized, modified, regulated, and controlled in living organisms according to the host cell. Protein expression in the context of protein research can now also refer to the application of lab procedures necessary for protein production. The main product types for protein expression are reagents, competent cells, expression vectors, services, and instruments. A reagent is a substance or compound that is added to a system in order to produce a chemical reaction or to determine whether or not a reaction occurred. The various forms of protein expression include yeast expression, mammalian expression, algae expression, insect expression, bacterial expression, and cell-free expression that are used for therapeutic, industrial, and research applications. The different end users involve pharmaceutical and biotechnology companies, academic research, and contract research organizations. The protein expression market research report is one of a series of new reports from The Business Research Company that provides protein expression market statistics, including protein expression industry global market size, regional shares, competitors with a protein expression market share, detailed protein expression market segments, market trends and opportunities, and any further data you may need to thrive in the protein expression industry. This protein expression market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global protein expression market will grow from $2.87 billion in 2022 to $3.19 billion in 2023 at a compound annual growth rate (CAGR) of 11.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global protein expression market is expected to grow to $4.96 billion in 2027 at a CAGR of 11.6%. An increase in demand for biologics to counter various genetic disorders and chronic diseases is one the major factors driving the research and sales of protein expression market. Biologics is a medicine produced from living organisms or contains components of living organisms such as protein, tissue, genes, allergens, cells, blood components, blood, and vaccines. The increasing use of biologics (therapeutic protein and others) to cure chronic diseases such as cancer, cardiovascular conditions and genetic disorders, is increasing the demand for protein expression devices and equipment. According to the World Health Organization, chronic disease prevalence rose by 57% globally, in the year 2020. Hence the rising demand for biologics is driving the protein expression market. For instance, according to an article published by Chemistry World, analysts stated that the biologics market hold a market share of more than a quarter of the entire pharmaceutical market in 2020. The global biologics market is expected to grow at 14.7% during 2021-2023. Government regulations related to protein therapeutics and the production of biologics may hinder the protein expression market growth. Government regulations on biologics to undergo rigorous preclinical and clinical trials prior to regulatory approval, and time-consuming process for approval of biologics with regards to health and the safety of any individual are restraining the market growth. Marketing and distribution of biologics including insulin, hormones, therapeutic antibodies, and vaccines depends upon the successful completion of clinical trials, which is a long, expensive, and uncertain process. According to FDA, for an approval of new biologic, Under the regulations (21 CFR 314.81(b)(2)(vii) and 601.70, a clinical trial approval usually takes 10- 12 months where firms are required to submit a report annually on the status of clinical safety, clinical efficiency, clinical pharmacology, and nonclinical toxicology study. Companies in the industry are increasingly adopting Microfluidics technology to enhance protein expression tests in order to reduce the time, cost, labor, and increase in the accuracy and performance. The microfluidics technology effectively analyzes biological samples than the traditional (macroscale) instruments. Microfluidics technology is used to measure the expression of proteins on cells and optimizes the output to generate results regarding protein expression. Therapeutics-on-a-chip (TOC) uses microfluidic platform and is able to synthesize proteins in a point-of-care setting to reduce cost associated with storage and transportation of therapeutic proteins. For instance, companies such as MissionBio, NanoCellect Biomedical, RainDance Technologies and Sphere fluidics have implemented this technology in protein expression test. The Protein Expression market in the U.S. is governed by the Food and Drug Administration (FDA) which lays down a series of guidelines for the manufacturers and retailers of this industry. Within FDA, Centre for Drug Evaluation and research (CDER) regulates biological products under FDA 101 which includes gene therapy products and vaccines. These regulations ensure the quality, safety, and efficacy of biological therapeutics products, and speed up innovations that make these products safer, and effective. The US FDA announced a fast-track initiative to review its drugs and biologics policy to speed the availability of therapies to patients with serious conditions, orphan drugs for rare disease, while preserving the safety and efficacy standards. FDA also removed a rule (Section 610.21 of the FDA code) that specified minimal potency limits for certain antibodies and antigens. The European Medicines Agency has also introduced policies that include a provision to waive the scientific advice fee, which encourages more academic groups and small companies to propose candidates for biologics. Major players in the protein expression market are Agilent Technologies, Bio-Rad Laboratories, Thermo Fisher Scientific Inc., New England Biolabs, Promega Corporation, Qiagen, Takara Bio, Merck KGaA, Genscript Biotech Corporation, Life Technologies Corporation, Sigma-Aldrich Corporation, Lucigen Corporation, Synthetic Genomics Inc., Becton, Dickinson & Company, Lonza Group Ltd., Accelagen Inc., Geneva Biotech, Viva Biotech, Becton, Dickinson & Company, Sengenics, ARTES Biotechnology GmbH, Addgene Inc., Profacgen, ProteoGenix, Peak Proteins Ltd., Domainex Ltd., Jena Bioscience GmbH, EMD Millipore, and Oxford Expression Technologies Ltd. North America was the largest region in the protein expression market in 2022. Western Europe was the second largest region in the global protein expression market. The regions covered in the global protein expression market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the protein expression market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The protein expression market includes revenue earned by instruments, expression kits, and systems. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global protein expression market is segmented - 1) By Protein Expression: Yeast Expression, Mammalian Expression, Algae Expression, Insect Expression, Bacterial Expression, Cell-free Expression 2) By End Use: Pharmaceutical And Biotechnological Companies, Academic Research, Contract Research Organizations 3) By Product: Reagents, Competent Cells, Expression vectors, Services, Instruments 4) By Application: Therapeutic, Industrial, Research

Engineering services can provide extensive consultation to a company needing expert advice and solutions. Engineering services firms can accept the project and work on evaluating, designing, simulating, and testing the product. The main types of engineering services are civil engineering services, environmental engineering services, construction engineering services, mechanical engineering services, and other engineering services. Civil engineering services encompass a wide range of activities, including the planning, design, and construction of commercial and residential structures; transportation infrastructure, such as roads, bridges, and railways; water distribution systems, such as dams, sewers, and sewage treatment; environmental infrastructure, such as landscaping, urban planning, and parks; industrial infrastructure construction management; construction technology; and more. The various engineering disciplines include civil, mechanical, electrical, piping, and structural engineering and are delivered through offshore and onsite models. The services are used by automotive, industrial manufacturing, healthcare sector, aerospace, telecommunications, information technology, energy & utilities, and others. The engineering services market research report is one of a series of new reports from The Business Research Company that provides engineering services market statistics, including engineering services industry global market size, regional shares, competitors with an engineering services market share, detailed engineering services market segments, market trends and opportunities, and any further data you may need to thrive in the engineering services industry. This engineering services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global engineering services market size will grow from $1,110.21 billion in 2022 to $1,156.5 billion in 2023 at a compound annual growth rate (CAGR) of 4.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global engineering services market size is expected to grow to $1,316.06 billion in 2027 at a CAGR of 3.3%. The engineering services market is expected to benefit from steady economic growth in developed and developing countries. The International Monetary Fund (IMF) predicts that global real GDP growth will be 3.6% from 2021 to 2023. This trend will be mainly driven by regions of Asia and Africa. According to the report, Asia will represent 66% of the global middle-class population by 2030. For instance, the Indian IT-BPM industry grew by 7.7% in FY 2017, with software products and engineering services reaching US$ 25 billion. Going forward, the Asia-Pacific and Middle Eastern regions are expected to be the fastest-growing markets in the engineering services, design, animation, and graphic design industries. Developing countries such as India and China have started to attract foreign investment to improve their infrastructure. This was mainly due to an increase in internet penetration, a growth in the population, and increasing economic activity. Lack of quality control and safety concerns by engineering firms may hinder the growth of the engineering services market. Defects or failures in construction activities result in high costs. These minor defects result in re-construction to make the facility's operations impaired. Increased costs and delays are the results of ineffective internal controls and safety measures that hamper the end-to-end quality. For instance, QuEST, an engineering services company, is facing difficulties caused by a lack of understanding, problems in the execution process, and inconsistency across various business units. Companies in the industry are incurring high maintenance and budgeting costs to develop new and advanced methods to combat issues of safety and control. The increasing popularity and adoption of the Internet of Things (IoT) across the globe is the latest trend in the engineering services market. The Internet of Things (IoT) is a system of inter-related devices enabling the transmission of data over a wide range of networks. IoT enables continuous innovations in real-time data analytics, design, and development products and helps businesses grow at a faster pace. Engineering service providers are increasingly using industrial IoT to improve and optimise their production processes with better energy usage, resource allocation, and asset management. For instance, PureSoftware, an engineering service company, has successfully integrated IoT into engineering services and built a steady IoT platform to improve accuracy and speed of retrieving data. India's IoT industry is expected to reach USD 15 billion by 2020, accounting for approximately 5% of the global market. The Construction Design and Management Regulation, also known as the CDM Regulations/CDM 2015, came into force on April 6, 2015. These are the regulations governing the engineering service providers with respect to construction projects of all sizes and types. This CDM regulation (2015) replaced the Construction (Design and Management) Regulation 2007, aiming to improve the overall health, safety, and welfare of the workers and professionals involved in construction. This regulation specifies the general requirements, states safety norms, and minimum welfare facilities required at the construction sites. In 2020, Wipro, an Indian software services exporter, acquired Eximius Design for $80 million. The acquisition is expected to strengthen Wipro’s market presence in the semiconductor ecosystem. Eximius Design is a California-based engineering services company focused on ASIC design, systems, and software engineering. Eximius Design was founded in the year 2013 and has design centres in the US, India, and Malaysia. Major players in the engineering services market are Tata Consulting Services (TCS), Infosys, WorleyParsons, Deaton Engineering, Inc., Aricent Group, Cybage Software Pvt. Ltd., EPAM Systems; Inc. and GlobalLogic. North America was the largest region in the engineering services market in 2022. Western Europe was the second largest region in the global engineering services market. The regions covered in the global engineering services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the engineering services market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The engineering services market consists of revenue earned by entities that advise, prepare feasibility studies, prepare preliminary and final plans and designs, provide technical services during the construction or installation phase, and inspect and evaluate engineering projects. Engineering services’ companies apply physical laws and principles of engineering in the design, development, and utilization of machines, materials, instruments, structures, processes, and systems. Engineering services include technical application of engineering in product designing, innovations and others in industries such as building construction, mining, power and energy, transportation, manufacturing and others. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced. It does not include revenues from resales either further along the supply chain or as part of other products. The global engineering services market is segmented - 1) By Type: Civil Engineering Services, Environmental Engineering Services, Construction Engineering Services, Mechanical Engineering Services, Other Engineering Services 2) By End User: Automotive, Industrial Manufacturing, Healthcare Sector, Aerospace, Telecommunications, Information Technology, Energy & Utilities, Other End Users 3) By Engineering Disciplines: Civil, Mechanical, Electrical, Piping and Structural Engineering 4) By Delivery Model: Offshore, Onsite

Protein labelling refers to the process of detecting or purifying the labelled protein and its binding partners by using the proper molecular labels. Most biological research uses one of three basic categories of protein labels: biotin, enzyme conjugates, or fluorescence probes. The main types of products in protein labelling are reagents, proteins, enzymes, probes or tags, and monoclonal antibodies. Monoclonal antibodies are created by cloning a single white blood cell. Every subsequent antibody generated in this manner may be traced back to a single parent cell. The different labelling methods include in-vitro labeling, and in-vivo labelling and are used in cell-based assays, fluorescence microscopy, immunological techniques, mass spectrometry, and protein microassays. The protein labelling market research report is one of a series of new reports from The Business Research Company that provides protein labelling market statistics, including the industry's global market size, regional shares, competitors with a protein labelling market share, detailed protein labelling market segments, market trends and opportunities, and any further data you may need to thrive in the protein labelling industry. This protein labelling market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global protein labelling market grew from $2.13 billion in 2022 to $2.35 billion in 2023 at a compound annual growth rate (CAGR) of 10.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The protein labelling market is expected to grow from $3.49 billion in 2027 at a CAGR of 10.4%. Increased spending on the R&D of proteomics and genomics is driving the growth of the protein labelling reagents market. Proteomics is the study of the overall protein content of a cell, tissue, or organism. Protein labelling methods before separation and analysis are essential during proteomic profiling approaches. For instance, the National Institutes of Health (NIH) of the United States, funded $37 billion for biomedical research. This funding is for life sciences research that supports study at a molecular level for the understanding of fundamental processes by which diseases develop, the identification of biomarkers that signal the presence of disease, or identification of genes or proteins responsible for the disease. The Novo Nordisk Foundation granted a grant of up to $1.5 million to the University of Copenhagen to establish a mass spectrometry facility, which marks a new and exciting step in protein research. Therefore, the increased spending on research and development of proteomics and genomics is driving the market. Drawbacks related to protein labelling techniques are expected to hinder the market. Label-free techniques are preferred over labelled techniques because of the drawbacks associated with them, such as wet-lab complexity and flexibility. While label-free samples can be measured without much preparation, wet lab pre-treatment is required for all labelling techniques. Samples must be labelled with metabolic (e.g. SILAC) or chemical (e.g. iTRAQ or TMT) reagents and the different conditions has to be combined. Therefore, label-free techniques are less prone to wet lab errors than labelling techniques. Label-free approaches have the advantage of being highly adaptable, even after the study has begun. New samples can be included at any time, but labelled approaches require the same number (n) of each condition. New samples may not be included in the study if they cannot be physically mixed and measured with the control. Labeled techniques such as the Super-SILAC approach reduce this problem but must also be carefully planned. These disadvantages are making label-free techniques preferable. Therefore, drawbacks associated with protein labeling techniques are expected to hinder the market. Companies in the protein labelling market are increasing their product innovation through strategic collaborations. To sustain in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated as well as academic and research institutions in this market by way of partnerships, in or out-licensing deals, this trend has been increasing over recent years. For instance, recombinant protein manufacturer enGenes Biotech GmbH (enGenes) announced a collaboration with ACIB GmbH for protein labeling. In January 2020, Abcam, a UK-based protein research tools producer and seller, announced its decision to acquire Expedeon's Proteomics and Immunology business, which includes Innova and TGR Biosciences. Expedeon technology supports a diverse set of labels, including enzymes, metals, oligos, and fluorescent proteins. Abcam will combine the newly acquired capture and conjugation technologies with its extensive antibody and protein expertise to expand and enhance its portfolio of off-the-shelf, and custom reagents and tools. Expedeon is a Germany-based manufacturer of protein discovery and analysis products used for protein and drug research. Major players in the protein labelling market are Thermo Fisher Scientific Inc., Merck KGaA, PerkinElmer, Inc., General Electric Company, F. Hoffmann-La Roche AG, AGILENT TECHNOLOGIES INC., BIO-RAD LABORATORIES, Kirkegaard & Perry Laboratories, LI-COR Inc. and Kaneka Corporation. North America was the largest region in the protein labeling market in 2022. The regions covered in the global protein labelling market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the protein labelling market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The protein labeling market includes revenues earned by entities by detecting or purifying the labelled protein and its binding partners. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global protein labelling market is segmented - 1) By Product: Reagents, Protein, Enzymes, Probes/ Tags, Monoclonal Antibodies 2) By Labeling Method: In-vitro Labeling, In-vivo Labeling 3) By Application: Cell Based-Assay, Fluorescence Microscopy, Immunological Techniques, Mass Spectrometry, Protein Micro Assay

Protein inhibitors refer to compounds that interfere with the steps directly involved in the production of new proteins in cells. Protein inhibitors operate at the ribosome level, benefiting from the significant variations between prokaryotic and eukaryotic ribosome architectures. The main product types of protein inhibitors are protein kinase inhibitors, monoclonal antibodies, and others. Monoclonal antibodies are laboratory-created molecules designed to act as substitute antibodies, restoring, enhancing, modifying, or mimicking the immune system's attack on unwanted cells, such as cancer cells. The protein inhibitors are used in the treatment of oncology, inflammatory diseases, and others, and are distributed by hospital pharmacies, independent pharmacies, and online pharmacies. The protein inhibitors market research report is one of a series of new reports from The Business Research Company that provides protein inhibitors market statistics, including protein inhibitors industry global market size, regional shares, competitors with a protein inhibitors market share, detailed protein inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the protein inhibitors industry. This protein inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global protein inhibitors market grew from $68.17 billion in 2022 to $74.3 billion in 2023 at a compound annual growth rate (CAGR) of 9.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The protein inhibitors market is expected to grow from $105.43 billion in 2027 at a CAGR of 9.1%. The increasing prevalence of chronic diseases is predicted to contribute to the growth of the protein inhibitors market over the forecast period. Chronic diseases such as cancer, cardiovascular diseases, and autoimmune diseases are becoming more prevalent. For instance, in May 2022, according to the World Health Organization, chronic diseases are expected to become the seventh leading cause of death globally by the end of 2030.In the USA, the number reached 157 million in 2020, with 87 million people having multiple conditions. Protein inhibitors are used for the treatment of these diseases attributing to fewer adverse effects and higher efficacy. Therefore, an increasing number of people with chronic diseases are anticipated to propel the demand for protein inhibitors market. The high cost of protein inhibitors used for cancer is anticipated to limit the growth of the protein inhibitors market shortly. Monoclonal antibodies are a type of protein made in the laboratory to bind substances in the body including cancer cells and are used to treat various types of cancer. Monoclonal antibody therapies are considered to be costlier when used for cancer. For instance, according to the National Center for Biotechnology Information, the average price of monoclonal antibodies was $96,731 for 34 monoclonal antibody indication combinations. Oncology and hematology monoclonal antibodies represented 40% of approved monoclonal antibody indication combinations, yet accounted for more than 85% of those priced at $100,000 or higher. The price of oncology or hematology monoclonal antibodies was $149,622 higher than those used in metabolic or cardiovascular disorders, $106,830 higher than in ophthalmology, $128,856 higher than in infectious diseases or allergies, and $98,981 higher than in immunology. Thus, the high cost of protein inhibitors including monoclonal antibodies for the treatment of cancer is expected to hinder the market’s growth. Companies in the protein inhibitors market are increasingly investing in various strategic initiatives such as partnerships and collaborations to develop new drugs to meet the market demand. Strategic collaborations and partnership agreements help companies to expand their existing product portfolio and geographical presence. For instance, in February 2020, Catalent, Inc., a USA-based provider of delivery technologies, drug manufacturing, gene therapies, biologics, and consumer healthcare products announced a partnership agreement with Zumutor Biologics Inc., an immune-oncology company based in the USA to manufacture ZM008, a monoclonal antibody targeting solid tumors. Moreover, in February 2021, Eli Lilly and Company, a USA-based pharmaceutical company, and Rigel Pharmaceuticals, Inc., a USA-based biotechnology company, announced a global exclusive license agreement and strategic collaboration to co-develop and commercialize Rigel's R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for all indications, including autoimmune and inflammatory diseases. In June 2022, Pfizer Inc., a US-based pharmaceutical and biotechnology company, acquired ReViral for $525 million. The acquisition strengthens Pfizer's commitment to creating both medications and vaccines to help fight the respiratory syncytial virus while also expanding its anti-infective portfolio (RSV). ReViral is a UK-based clinical-stage biopharmaceutical company pioneering in the discovery and development of innovative antiviral drugs for disorders brought on by the respiratory syncytial virus. Major players in the protein inhibitors market are Bayer AG, Astra Zeneca, Roche, Teva, Apotex, Novartis, GlaxoSmithKline, Pfizer, Boehringer Ingelheim, and F. Hoffmann-La Roche. North America was the largest region in the protein inhibitors market in 2022. The regions covered in the global protein inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the global protein inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The protein inhibitors market consists of sales of erythromycin, tetracycline, chloramphenicol, and aminoglycosides. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global protein inhibitors market is segmented - 1)By Product: Protein Kinase Inhibitors, Monoclonal Antibody, Other Products 2)By Application: Oncology, Inflamatory Diseases, Other Applications 3)By Distribution Channel: Hospital Pharmacies, Independent Pharmacies, Online Pharmacies

Protein inhibitors refer to compounds that interfere with the steps directly involved in the production of new proteins in cells. Protein inhibitors operate at the ribosome level, benefiting from the significant variations between prokaryotic and eukaryotic ribosome architectures. The main product types of protein inhibitors are protein kinase inhibitors, monoclonal antibodies, and others. Monoclonal antibodies are laboratory-created molecules designed to act as substitute antibodies, restoring, enhancing, modifying, or mimicking the immune system's attack on unwanted cells, such as cancer cells. The protein inhibitors are used in the treatment of oncology, inflammatory diseases, and others, and are distributed by hospital pharmacies, independent pharmacies, and online pharmacies. The protein inhibitors market research report is one of a series of new reports from The Business Research Company that provides protein inhibitors market statistics, including protein inhibitors industry global market size, regional shares, competitors with a protein inhibitors market share, detailed protein inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the protein inhibitors industry. This protein inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global protein inhibitors market grew from $68.17 billion in 2022 to $74.3 billion in 2023 at a compound annual growth rate (CAGR) of 9.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The protein inhibitors market is expected to grow from $105.43 billion in 2027 at a CAGR of 9.1%. The increasing prevalence of chronic diseases is predicted to contribute to the growth of the protein inhibitors market over the forecast period. Chronic diseases such as cancer, cardiovascular diseases, and autoimmune diseases are becoming more prevalent. For instance, in May 2022, according to the World Health Organization, chronic diseases are expected to become the seventh leading cause of death globally by the end of 2030.In the USA, the number reached 157 million in 2020, with 87 million people having multiple conditions. Protein inhibitors are used for the treatment of these diseases attributing to fewer adverse effects and higher efficacy. Therefore, an increasing number of people with chronic diseases are anticipated to propel the demand for protein inhibitors market. The high cost of protein inhibitors used for cancer is anticipated to limit the growth of the protein inhibitors market shortly. Monoclonal antibodies are a type of protein made in the laboratory to bind substances in the body including cancer cells and are used to treat various types of cancer. Monoclonal antibody therapies are considered to be costlier when used for cancer. For instance, according to the National Center for Biotechnology Information, the average price of monoclonal antibodies was $96,731 for 34 monoclonal antibody indication combinations. Oncology and hematology monoclonal antibodies represented 40% of approved monoclonal antibody indication combinations, yet accounted for more than 85% of those priced at $100,000 or higher. The price of oncology or hematology monoclonal antibodies was $149,622 higher than those used in metabolic or cardiovascular disorders, $106,830 higher than in ophthalmology, $128,856 higher than in infectious diseases or allergies, and $98,981 higher than in immunology. Thus, the high cost of protein inhibitors including monoclonal antibodies for the treatment of cancer is expected to hinder the market’s growth. Companies in the protein inhibitors market are increasingly investing in various strategic initiatives such as partnerships and collaborations to develop new drugs to meet the market demand. Strategic collaborations and partnership agreements help companies to expand their existing product portfolio and geographical presence. For instance, in February 2020, Catalent, Inc., a USA-based provider of delivery technologies, drug manufacturing, gene therapies, biologics, and consumer healthcare products announced a partnership agreement with Zumutor Biologics Inc., an immune-oncology company based in the USA to manufacture ZM008, a monoclonal antibody targeting solid tumors. Moreover, in February 2021, Eli Lilly and Company, a USA-based pharmaceutical company, and Rigel Pharmaceuticals, Inc., a USA-based biotechnology company, announced a global exclusive license agreement and strategic collaboration to co-develop and commercialize Rigel's R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for all indications, including autoimmune and inflammatory diseases. In June 2022, Pfizer Inc., a US-based pharmaceutical and biotechnology company, acquired ReViral for $525 million. The acquisition strengthens Pfizer's commitment to creating both medications and vaccines to help fight the respiratory syncytial virus while also expanding its anti-infective portfolio (RSV). ReViral is a UK-based clinical-stage biopharmaceutical company pioneering in the discovery and development of innovative antiviral drugs for disorders brought on by the respiratory syncytial virus. Major players in the protein inhibitors market are Bayer AG, Astra Zeneca, Roche, Teva, Apotex, Novartis, GlaxoSmithKline, Pfizer, Boehringer Ingelheim, and F. Hoffmann-La Roche. North America was the largest region in the protein inhibitors market in 2022. The regions covered in the global protein inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the global protein inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The protein inhibitors market consists of sales of erythromycin, tetracycline, chloramphenicol, and aminoglycosides. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global protein inhibitors market is segmented - 1)By Product: Protein Kinase Inhibitors, Monoclonal Antibody, Other Products 2)By Application: Oncology, Inflamatory Diseases, Other Applications 3)By Distribution Channel: Hospital Pharmacies, Independent Pharmacies, Online Pharmacies

Protein supplements refer to a nutritional supplement that contains protein and is intended to supplement the diet. A protein supplement helps in building muscle, repairing tissue, and producing enzymes and hormones. It also aids in weight loss and assists in toning of muscles for athletes. The main types of protein supplements include protein powder, protein bars, and ready-to-drink products. Protein powder refers to powdered forms of protein that are derived from plants (soybeans, peas, rice, potatoes, or hemp), eggs, or milk (casein or whey protein). Other components, such as extra sugar, artificial flavors, thickeners, vitamins, and minerals, are added to enhance the flavor and functionality of the powder. Based on raw material, the protein supplements are differentiated by casein protein supplements, whey protein supplements, egg protein supplements, MPC protein supplements, and soy protein supplements. The animal-derived and plant-derived protein supplements are sold through supermarkets, hypermarkets, online stores, and drug stores. The protein supplements market research report is one of a series of new reports from The Business Research Company that provides protein supplements market statistics, including protein supplements industry global market size, regional shares, competitors with a protein supplements market share, detailed protein supplements market segments, market trends and opportunities, and any further data you may need to thrive in the protein supplements industry. This protein supplements market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global protein supplements market size grew from $18.75 billion in 2022 to $20.62 billion in 2023 at a compound annual growth rate (CAGR) of 10.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services, and affecting many markets across the globe. The protein supplements market size is expected to grow to $29.51 billion in 2027 at a CAGR of 9.4%. The rise in customer preference for food supplements is driving the protein supplements market. Food Supplements are intended to make up for dietary deficiencies among individuals through their regular diet. The desire to lead active and healthy lifestyles has increased participation in sports and fitness activities, driving the demand for food supplements, especially protein supplements. According to the Council for Responsible Nutrition survey 2020, a US-based trade association for ingredient suppliers and manufacturers in the dietary supplement industry, approximately 43% of supplement users have altered their supplement regimens after the pandemic, whereas 91% of these users report an increase in supplement intake, including the addition of new supplements to an existing routine (46%), the taking of the same supplements more frequently (25%), or the increasing of doses (22%). Thus, an increase in customer preference for food supplements is expected to boost the demand for protein supplements during the forecast period. Strategic partnership is a key trend gaining popularity in the protein supplements market. The companies operating in the protein supplement sector are focusing on entering into strategic partnerships to expand their market reach and leverage each other's resources in new product development & marketing activities. In October 2021, a New Jersey-based company that creates collagen supplements entered into a partnership with Entenmann's, owed by Bimbo Bakeries USA. The partnership aims to create a new collagen protein powder with Entenmann's chocolate chip cookies as inspiration. Entenmann is a US-based company that manufactures and delivers baked goods. In February 2022, Nestle Health Sciences, a Switzerland-based provider of nutrition solutions, diagnostics devices, and drugs for specific target areas acquired a majority stake in Orgain, for an undisclosed amount. Through this, Nestle is focused on expanding its product portfolio in the plant-based protein supplement sector and enhancing its business presence in the fast-growing plant-based product sector across the globe. Orgain is a California-based provider of plant-based nutritional products. Major players in the protein supplements market are GlaxoSmithKline (GSK), Glanbia PLC, ABBOTT LABORATORIES (ABBOTT), Amway Corporation, Herbalife International of America, Inc., PepsiCo, AMCO Proteins, QuestNutrition, GNC Holdings, Maker Nutrition LLC, SUPPLEFORM, Vitaco Health Limited, Garden of Life, Melaleuca Inc., Atlantic Multipower UK Limited, International Dehydrated Foods, Inc., Scitec Nutrition, and BRF. North America was the largest region in the protein supplements market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the protein supplements market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the protein supplements market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The protein supplements market consists of sales of soybean meal, essential amino acid, protein intake, proteins, amino acids, whey protein. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global protein supplements market is segmented - 1) By Type: Protein Powder, Protein Bar, Ready to Drink 2) By Source: Plant-based, Animal-based 3) By Raw Material: Casein Protein Supplements, Whey Protein Supplements, Egg Protein Supplements, MPC Protein Supplements, Soy Protein Supplements 4) By Distribution Channel: Supermarkets & Hypermarkets, Online Stores, Drug Stores

Engineering plastics are high-performance synthetic resins with high durability and heat resistance that have better mechanical and thermal properties. These resins are a class of plastic polymers that offer superior qualities over the more popular commodity plastics. The engineering plastics have the ability to withstand adverse mechanical and environmental conditions. The main types of engineering plastics are acrylonitrile butadiene styrene, polyamide, polycarbonate, thermoplastic polyester, polyacetal, fluoropolymer, and others. Acrylonitrile Butadiene Styrene (ABS) is used for injection molding applications. It is popular due to its low production cost. Acrylonitrile Butadiene Styrene (ABS) is a terpolymer made by polymerizing styrene and acrylonitrile in the presence of polybutadiene. The different performance parameters include high performance and low performance, and are employed in automotive and transportation, consumer appliances, electrical and electronics, industrial and machinery, packaging, and other end-use industries. The engineering plastics market research report is one of a series of new reports from The Business Research Company that provides engineering plastics market statistics, including engineering plastics industry global market size, regional shares, competitors with engineering plastics market share, detailed engineering plastics market segments, market trends and opportunities, and any further data you may need to thrive in the engineering plastics industry. This anomaly detection market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global engineering plastics market size grew from $96.04 billion in 2022 to $104.99 billion in 2023 at a compound annual growth rate (CAGR) of 9.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The engineering plastics market size is expected to grow to $145.11 billion in 2027 at a CAGR of 8.4%. The growth in the electronics and electrical industries is expected to propel the growth of the engineering plastics market going forward. The electronics industry produces consumer electronics, electrical equipment, and electrical components for a variety of products. Engineering plastics are used in the manufacturing of various electronic goods such as computers, communication equipment, switchgear, storage batteries, and switchboards. For instance, according to the Ministry of Electronics and Information Technology, an India-based government agency, the electronics manufacturing industry is expected to grow from USD 75 billion in 2022 to USD 300 billion by 2026. Therefore, the growth in the electronics and electrical industries is driving the demand for the engineering plastics market. Bio-based or recycled-based materials have emerged as a key trend gaining popularity in the engineering plastics market. Major companies operating in the engineering plastics market are focused on developing bio-based or recycled-based materials as alternatives for plastics solutions to strengthen their position in the market. For instance, in August 2022, Toray Industries, Inc., a Japan-based producer of engineering plastics such as PPS, nylon, and PBT, developed the first ever fully bio-based adipic acid, a component of nylon 66 (polyamide 66), made from sugars extracted from non-edible feedstock. The company's microbial fermentation technology and chemical purification technology, which makes use of separation membranes, were combined in a unique synthesis method to accomplish this success. In May 2022, RadiciGroup, an Italy-based manufacturer and supplier of engineering polymers, acquired Ester Industries Ltd.’s engineering plastics business for $ 37 million. With this acquisition, RadiciGroup would be able to increase its already significant commercial presence in the Indian market. Ester Industries is an India-based manufacturer of engineering plastics. Major players in the engineering plastics market are Covestro AG, Du Pont de Nemours & Company, LG Chem Ltd., Evonik Industries AG, Mitsubishi Chemical Engineering Corporation, BASF SE, Celanese Corporation, Solvay S.A, Saudi Basic Industries Corporation, Lanxess AG, and E. I. du Pont de Nemours and Company. Asia-Pacific was the largest region in the engineering plastics market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the engineering plastics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the engineering plastics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The engineering plastics market consists of sales of polyetheretherketone, nylon 6, and polyetherimide (PEI). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global engineering plastics market is segmented - 1) By Type: Acrylonitrile Butadiene Styrene, Polyamide, Polycarbonate, Thermoplastic Polyester, Polyacetal, Fluoropolymer, Other Types 2) By Performance Parameter: High Performance, Low Performance 3) By End-Use Industry: Automotive And Transportation, Consumer Appliances, Electrical And Electronics, Industrial And Machinery, Packaging, Other End-Use Industries

Proteomics is the study of the structure and functions of proteins that are used in drug discovery, diagnosis, and treatment of diseases. Proteomics is used to evaluate the protein production rate, the involvement of proteins in metabolic pathways, and the modifications of proteins. The main types of proteomics are protein microarrays, spectroscopy, X-ray crystallography, chromatography, electrophoresis, surface plasmon resonance, and protein fractionation. The various components used are reagents, instruments, and software that are used for proteomic analytical services and instrument services. The proteomics market research report is one of a series of new reports from The Business Research Company that provides proteomics market statistics, including proteomics industry global market size, regional shares, competitors with a proteomics market share, detailed proteomics market segments, market trends, and opportunities, and any further data you may need to thrive in the proteomics industry. This proteomics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global proteomics market grew from $26.98 billion in 2022 to $31.28 billion in 2023 at a compound annual growth rate (CAGR) of 15.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The proteomics market is expected to grow from $50.79 billion in 2027 at a CAGR of 12.9%. Rising government funds for research on proteomics drives the growth of the proteomics market. Government funds help researchers in drug discovery, diagnosis, and treatment of diseases. For instance, in 2020, the IRB Barcelona's Mass Spectrometry and Proteomics Core Facility, which is led by a research team with extensive expertise in the field, has received funding from the Catalan government through the European Regional Development Fund (ERDF) to purchase next-generation protein analysis equipment in collaboration with the Josep Carreras Leukemia Research Institute (IJC), the Sant Joan de Déu Research Institute (SJD), the Vall d'Hebron Institute of Oncology (VHIO), and the (UB). Therefore, rising government funds positively impacts the proteomics market. The high cost of instruments is expected to limit the growth of the proteomics market. The broad implementation of new technologies expands the use of proteomics research from the discovery of new drugs, vaccines, and diagnostic targets, and due to its high-cost process, developments in different instruments have resulted in high prices compared to the traditional ones. For instance, the price of mass spectrometers can range from $20,000 to $300,000, which will be extremely expensive for small-scale pharmaceutical companies and academic institutions. Therefore, the high prices associated with proteomics instruments make it difficult for developing countries to enter the proteomics sector, affecting the market’s growth. Companies are launching new products in order to increase their revenue and also gain a competitive edge over their rivals. For instance, in June 2021, Bruker Corporation, a USA-based scientific instruments manufacturing company, announced the availability of two new trapped ion mobility spectrometry time-of-flight (timsTOF) instruments at its 4D-Proteomics eXceed Symposium. The devices, which are based on ion mobility separation and mass spectrometry, will provide additional advances in proteomics, epiproteomics/PTM characterisation, and deep multiomic biomarker discovery. In January 2020, Abcam, a UK-based company specialized in manufacturing research-grade antibodies, acquired Expedeon's proteomics and immunology business for an undisclosed amount. The acquisition is expected to help Abcam enhance its protein conjugation technology and create new products to support research and diagnostic development. Expedeon Ltd. is a UK-based company that specializes in the development of next-generation tools for biological research, diagnostics, and drug discovery. Major players in the proteomics market are Thermo Fisher Scientific Inc., Agilent Technologies Inc., Danaher Corporation, Merck KGaA, Waters Corporation, Perkinelmer Inc., Bio-Rad Laboratories Inc., Bruker Corporation, GE Healthcare, Caprion Biosciences, Luminex Corporation, LI-COR Inc., Becton Dickinson and Company, Siemens Ltd., Genzyme Corporation, Creative Proteomics, and Promega Corporation. North America was the largest region in the proteomics market in 2022. Western Europe was the second largest region in the global proteomics market. The regions covered in the global proteomics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the proteomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The proteomics market consists of sales of proteins that are used for drug discovery, clinical diagnosis, molecular medicine and others. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global proteomics market is segmented - 1) By Component: Reagents, Instruments 2) By Instrument: Protein Microarrays, Spectroscopy, X-ray Crystallography, Chromatography, Electrophoresis, Surface Plasmon Resonance, Protein Fractionation 3) By Service and Software: Core Proteomics Services, Bioinformatics Software & Services